These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 35111165)

  • 1. Replacement and Immunomodulatory Activities of 20% Subcutaneous Immunoglobulin Treatment: A Single-Center Retrospective Study in Autoimmune Myositis and CVID Patients.
    Danieli MG; Verga JU; Mezzanotte C; Terrenato I; Svegliati S; Bilo MB; Moroncini G
    Front Immunol; 2021; 12():805705. PubMed ID: 35111165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases.
    Cherin P; Belizna C; Cartry O; Lascu-Dubos G; de Jaeger C; Delain JC; Crave JC; Hachulla E
    Autoimmun Rev; 2016 Mar; 15(3):281-6. PubMed ID: 26688441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis.
    Danieli MG; Moretti R; Gambini S; Paolini L; Gabrielli A
    Clin Rheumatol; 2014 Apr; 33(4):531-6. PubMed ID: 24395197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A machine learning analysis to predict the response to intravenous and subcutaneous immunoglobulin in inflammatory myopathies. A proposal for a future multi-omics approach in autoimmune diseases.
    Danieli MG; Tonacci A; Paladini A; Longhi E; Moroncini G; Allegra A; Sansone F; Gangemi S
    Autoimmun Rev; 2022 Jun; 21(6):103105. PubMed ID: 35452850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovering autonomy is a key advantage of home-based immunoglobulin therapy in patients with myositis: A qualitative research study.
    Chérin P; Pindi Sala T; Clerson P; Dokhan A; Fardini Y; Duracinsky M; Crave JC; Chassany O
    Medicine (Baltimore); 2020 Feb; 99(7):e19012. PubMed ID: 32049796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of renal function in patients with myositis and treated with subcutaneous immunoglobulin: a series of 24 cases.
    Cherin P; Tadmouri A; de Jaeger C; Pindi Sala T; Crave JC
    Ther Adv Musculoskelet Dis; 2018 Oct; 10(10):201-207. PubMed ID: 30327686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
    Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
    J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuts and Bolts of Subcutaneous Therapy.
    Duff C; Ballow M
    Immunol Allergy Clin North Am; 2020 Aug; 40(3):527-537. PubMed ID: 32654697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
    Gandiga PC; Ghetie D; Anderson E; Aggrawal R
    Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
    Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
    Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
    Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R
    PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
    Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
    Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases.
    Kobayashi RH; Litzman J; Rizvi S; Kreuwel H; Hoeller S; Gupta S
    Immunotherapy; 2022 Mar; 14(4):259-270. PubMed ID: 34986666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
    Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
    Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
    Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
    J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
    Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
    Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis.
    Abolhassani H; Sadaghiani MS; Aghamohammadi A; Ochs HD; Rezaei N
    J Clin Immunol; 2012 Dec; 32(6):1180-92. PubMed ID: 22730009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
    Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
    J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
    Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
    Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.